Treatment guidelines recommend omega-3 with Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA) content not above 85% in patients with high plasma levels of triglycerides. Since the different up to date formulation of omega-3 available in commerce must be similar to clinical efficacy and safety, herein, we report the case a 52-year-old woman who presented clinical inefficacy using Olevia(®) omega-3 treatment. Clinical evaluation excluded the presence of intestinal or systemic diseases able to reduce the drug absorption. Switching the therapy from (Olevia(®)) to an equivalent omega-3 formulation (Esapent(®)), we documented a decrease in her plasma triglycerides levels. In order to evaluate a possible difference between these formulations we performed a single blind in vitro dissolution test using three pills for each formulation of omega-3 (Olevia(®), Esapent® and another one chosen between the several formulations available in commerce: DOC Generic(®)) that revealed a significant difference (>20%) in the dissolution time of three different omega- 3 commercially available drug formulation.

Different Omega-3 Formulations Yield to Diverse Clinical Response: A Case-Report / Gallelli, Luca; Michniewicz, Andzelika; Stefanelli, Roberta; Cannataro, Roberto; Longo, Paola; Perri, Mariarita; Cione, Erika; Caroleo, Maria C. - In: CURRENT DRUG SAFETY. - ISSN 1574-8863. - 11:2(2016), p. 177-80. [10.2174/1574886311666151106120928]

Different Omega-3 Formulations Yield to Diverse Clinical Response: A Case-Report

Stefanelli, Roberta;
2016

Abstract

Treatment guidelines recommend omega-3 with Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA) content not above 85% in patients with high plasma levels of triglycerides. Since the different up to date formulation of omega-3 available in commerce must be similar to clinical efficacy and safety, herein, we report the case a 52-year-old woman who presented clinical inefficacy using Olevia(®) omega-3 treatment. Clinical evaluation excluded the presence of intestinal or systemic diseases able to reduce the drug absorption. Switching the therapy from (Olevia(®)) to an equivalent omega-3 formulation (Esapent(®)), we documented a decrease in her plasma triglycerides levels. In order to evaluate a possible difference between these formulations we performed a single blind in vitro dissolution test using three pills for each formulation of omega-3 (Olevia(®), Esapent® and another one chosen between the several formulations available in commerce: DOC Generic(®)) that revealed a significant difference (>20%) in the dissolution time of three different omega- 3 commercially available drug formulation.
2016
Docosahexaenoic Acids; Drug Compounding; Drug Substitution; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Female; Humans; Middle Aged; Single-Blind Method; Triglycerides
01 Pubblicazione su rivista::01a Articolo in rivista
Different Omega-3 Formulations Yield to Diverse Clinical Response: A Case-Report / Gallelli, Luca; Michniewicz, Andzelika; Stefanelli, Roberta; Cannataro, Roberto; Longo, Paola; Perri, Mariarita; Cione, Erika; Caroleo, Maria C. - In: CURRENT DRUG SAFETY. - ISSN 1574-8863. - 11:2(2016), p. 177-80. [10.2174/1574886311666151106120928]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1493507
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 0
social impact